نتایج جستجو برای: genomic targeted therapy

تعداد نتایج: 883589  

Journal: :Frontiers in oncology 2015
Stefan Symeonides Charlie Gourley

Only two new drugs have been licensed for the treatment of epithelial ovarian cancer in the last 5 years (bevacizumab and olaparib). These are also the only two molecularly targeted agents licensed in this disease. As we continue to move into the genomic era of cancer therapy, it is clear that optimal therapy is going to depend on molecular stratification and that the stratification itself is g...

Journal: :Genome research 2014
Dan E Webster Brook Barajas Rose T Bussat Karen J Yan Poornima H Neela Ross J Flockhart Joanna Kovalski Ashley Zehnder Paul A Khavari

Thousands of putative enhancers are characterized in the human genome, yet few have been shown to have a functional role in cancer progression. Inhibiting oncokinases, such as EGFR, ALK, ERBB2, and BRAF, is a mainstay of current cancer therapy but is hindered by innate drug resistance mediated by up-regulation of the HGF receptor, MET. The mechanisms mediating such genomic responses to targeted...

Journal: :Neuropathology and applied neurobiology 2012
K Masui T F Cloughesy P S Mischel

The classification of malignant gliomas is moving from a morphology-based guide to a system built on molecular criteria. The development of a genomic landscape for gliomas and a better understanding of its functional consequences have led to the development of internally consistent molecular classifiers. However, development of a biologically insightful classification to guide therapy is still ...

2016
Anthony Gonçalves François Bertucci Arnaud Guille Severine Garnier José Adelaide Nadine Carbuccia Oliver Cabaud Pascal Finetti Serge Brunelle Gilles Piana Jeanne Tomassin-Piana Maria Paciencia Eric Lambaudie Cornel Popovici Renaud Sabatier Carole Tarpin Magali Provansal Jean-Marc Extra François Eisinger Hagay Sobol Patrice Viens Marc Lopez Christophe Ginestier Emmanuelle Charafe-Jauffret Max Chaffanet Daniel Birnbaum

BACKGROUND Routine feasibility and clinical impact of genomics-based tumor profiling in advanced breast cancer (aBC) remains to be determined. We conducted a pilot study to evaluate whether precision medicine could be prospectively implemented for aBC patients in a single center and to examine whether patient-derived tumor xenografts (PDX) could be obtained in this population. RESULTS Thirty-...

Journal: :Clinical advances in hematology & oncology : H&O 2015
Weiqiang Gao Elihu Estey

Advances in genomic sequencing and insights into molecular leukemogenesis are opening the door to using targeted agents to tailor treatment for acute myeloid leukemia (AML) in individual patients. Although this shift away from traditional cytotoxic therapies represents an innovative approach to AML therapy, a number of obstacles stand in the way of widespread adoption of targeted therapy into d...

Journal: :Chinese clinical oncology 2015
Khanh Do Geraldine O'Sullivan Coyne Alice P Chen

The concept of oncogene addiction was first proposed by Weinstein in 2002, postulating that tumors rely on a single dominant mutation, the oncogenic "driver", for growth and survival. We have since come to realize that the genomic landscape of tumors is heterogeneous and more complex than previously thought. Advances in biotechnology and bioinformatics over the past decade have shifted treatmen...

Journal: :Asian Pacific journal of cancer care 2022

Background and objective: Tumor mutational burden (TMB) microsatellite instability (MSI) are predictive clinical markers of responses to immunotherapy in a wide range advanced cancers, including colorectal cancers. The data about TMB MSI Indian patients is scarce. Hence, assessed the incidence MSI, TMB, actionable alterations genes with metastatic carcinoma. Methods: A single centre, observatio...

2016
Stefania Trino Luciana De Luca Ilaria Laurenzana Antonella Caivano Luigi Del Vecchio Giovanni Martinelli Pellegrino Musto

The tumor suppressor p53 is a canonical regulator of different biological functions, like apoptosis, cell cycle arrest, DNA repair, and genomic stability. This gene is frequently altered in human tumors generally by point mutations or deletions. Conversely, in acute lymphoblastic leukemia (ALL) genomic alterations of TP53 are rather uncommon, and prevalently occur in patients at relapse or with...

2017
LD Fiore MT Brophy RE Ferguson C Shannon SJ Turek K Pierce‐Murray S Ajjarapu GD Huang CSE Lee PW Lavori

Cancer genomic research reveals that a similar cancer clinical phenotype (e.g., non-small cell lung cancer) can arise from various mutations in tumor DNA. Thus, organ of origin is not a definitive classification. Further, targeted therapy for cancer patients (precision oncology) capitalizes on knowledge of individual patient mutational status to deliver treatment directed against the protein pr...

2016
Quitterie Fontanges Ricardo De Mendonca Isabelle Salmon Marie Le Mercier Nicky D’Haene

Promising targeted therapy and personalized medicine are making molecular profiling of tumours a priority. For colorectal cancer (CRC) patients, international guidelines made RAS (KRAS and NRAS) status a prerequisite for the use of anti-epidermal growth factor receptor agents (anti-EGFR). Daily, new data emerge on the theranostic and prognostic role of molecular biomarkers, which is a strong in...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید